Therefore, IDH and TP53 (or ATRX) mutant gliomas are categorized into diffuse (WHO grade II) or anaplastic (WHO grade III) astrocytomas, IDH-mutant in the revised WHO classification. This evidence concerns the gene IDH1 and central nervous system cancer.